Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles (MicroTEC)

This study has been completed.
Massachusetts General Hospital
North Shore Medical Center
University of Southern California
VA Boston Healthcare System
Information provided by (Responsible Party):
Jeffrey Zwicker, MD, Dana-Farber Cancer Institute Identifier:
First received: May 26, 2009
Last updated: October 22, 2013
Last verified: October 2013
Research studies have shown a strong association between cancer and blood clots in the veins (also known as deep vein thrombosis). These blood clots can flow to the lungs (pulmonary embolism) which in severe cases may be life threatening. The purpose of this research study is to see if enoxaparin is effective in preventing blood clots in the veins in participants who have cancer of the pancreas, colorectal, non-small cell lung, ovary, or gastric and also have high levels of tissue factor bearing microparticles in their blood (TFMP). TFMP are small particles that are generated from different types of blood cells in the body. In people who have cancer, TFMP are thought to be generated from cancer cells and may represent a risk factor for deep vein thrombosis. Enoxaparin has been used to prevent formation of blood clots in patients after abdominal or orthopedic surgery and in patients who suffer from a severe medical illness. Based on these studies, we are investigating to see if it prevents thrombosis in people with certain types of cancer.

Condition Intervention Phase
Advanced Pancreatic, Colon, Lung, Gastric and Ovarian Cancer
Drug: Enoxaparin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles

Resource links provided by NLM:

Further study details as provided by Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • The Cumulative Incidence of VTE at 2 Months. [ Time Frame: 2 months ]
    The cumulative incidence of VTE at 2 months in the higher Venous thromboembolic events in cancer patients with high levels of circulating tissue factor bearing microparticles (TFMP).

Secondary Outcome Measures:
  • To Investigate the Safety of Prophylactic Enoxaparin in Cancer Patients (Major Bleeding Episodes). [ Time Frame: 2 months ]
  • To Assess the Impact of Enoxaparin on Overall Survival. [ Time Frame: years ]

Enrollment: 70
Study Start Date: May 2009
Study Completion Date: October 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A (high TFMP)
Enoxaparin given subcutaneously daily for 2 months
Drug: Enoxaparin
Given subcutaneously daily for 2 months
No Intervention: Arm B (high TFMP)
No Intervention: Arm C (low TFMP)

Detailed Description:
  • Because no one knows which of the study options is best, participants will be randomized into one of the following study groups. Participants who have high levels of TFMP in their blood will be in one of the two arms indicated.
  • Arm A (High TFMP): Enoxaparin given subcutaneously (into the skin) daily for 2 months, and lower extremity ultrasound performed at 2 months.
  • Arm B (High TFMP): Observation, lower extremity ultrasound performed at 2 months.
  • Arm C (Low TFMP): Observation, lower extremity ultrasound performed at 2 months.
  • At 2 months, participants will have a physical examination and will be asked questions about their general health and specific questions about any problems they might be having. They will also have a lower extremity ultrasound and blood tests performed at 2 months.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed malignancy that is metastatic or unresectable and for which standard curative therapies do not exist. Eligible malignancies include:

    • Adenocarcinoma of the pancreas (locally advanced or metastatic)
    • Colorectal (stage IV)
    • Non-small cell lung (unresectable stage III or IV)
    • Relapsed ovarian or stage IV
    • Surgically unresectable or metastatic gastric adenocarcinoma
  • First or second line therapy (within 4 weeks of initiating therapy).
  • Minimum age 18 years
  • Life expectancy of greater than 6 months
  • ECOG Performance Status 0, 1, or 2 (Karnofsky 60% or greater).
  • Participants must have normal organ and marrow function as outlined in the protocol.

Exclusion Criteria:

  • Participants may not be receiving any other study agents.
  • Known brain metastases should be excluded from this clinical trial because of their poor prognosis and higher potential for intracranial hemorrhage.
  • Prior history of documented venous thromboembolic event or pulmonary embolism within the last 5 years years (excluding central line associated events whereby patients completed anticoagulation > 3 months previously)
  • Active bleeding or high risk for bleeding (e.g. known acute gastrointestinal ulcer)
  • Any history of significant hemorrhage (requiring hospitalization or transfusion) outside of a surgical setting within the last 5 years
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to enoxaparin or heparin.
  • History of heparin-induced thrombocytopenia
  • Presence of coagulopathy (PT or PTT> 1.5 x upper limit of normal)
  • Familial bleeding diathesis
  • Known diagnosis of disseminated intravascular coagulation
  • Currently receiving anticoagulant therapy
  • Current use of aspirin (>81mg daily), Clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox), or regular use of non-steroidal anti-inflammatory agents more than twice weekly. Maximum dose of ibuprofen is 400mg no more than twice per week.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00908960

United States, California
University of Southern California-Keck School of Medicine
Los Angeles, California, United States, 90033
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02115
VA Boston Healthcare System
Boston, Massachusetts, United States, 02130
Mass General/North Shore Cancer Center
Danvers, Massachusetts, United States, 01923
Sponsors and Collaborators
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
North Shore Medical Center
University of Southern California
VA Boston Healthcare System
Principal Investigator: Jeffrey Zwicker, MD Beth Israel Deaconess Medical Center
  More Information

Responsible Party: Jeffrey Zwicker, MD, Attending Physician, Dana-Farber Cancer Institute Identifier: NCT00908960     History of Changes
Other Study ID Numbers: 08-378
Study First Received: May 26, 2009
Results First Received: July 22, 2013
Last Updated: October 22, 2013

Keywords provided by Dana-Farber Cancer Institute:

Additional relevant MeSH terms:
Coagulants processed this record on May 25, 2017